This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wolf, M. Articles by Thadhani, R. Search for Related Content PubMed PubMed Citation Articles by Wolf, M. Articles by Thadhani, R.

First Trimester Insulin Resistance and Subsequent Preeclampsia: A Prospective Study

Renal Unit, Departments of Medicine and Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114

Address all correspondence and requests for reprints to: Myles Wolf, M.D., Bulfinch 127, 55 Fruit Street, Massachusetts General Hospital, Boston, Massachusetts 02114. E-mail: . mswolf{at}partners.org

Abstract

Insulin resistance is implicated in the pathogenesis of preeclampsia, but prospective data are limited. SHBG, a marker of insulin resistance among nonpregnant individuals, has not been studied in detail during pregnancy. We conducted a prospective, nested, case-control study to test the hypothesis that increased insulin resistance, marked by reduced first trimester SHBG levels, is associated with increased risk of subsequent preeclampsia. First trimester SHBG levels were measured in 45 nulliparous women who subsequently developed preeclampsia (blood pressure, 140/90 mm Hg; proteinuria, either 2+ by dipstick or 300 mg/24 h, after 20 wk gestation) and in 90 randomly selected normotensive nulliparous controls. Compared with controls, women who developed preeclampsia had significantly reduced first trimester SHBG levels (302 ± 130 vs. 396 ± 186 nmol/liter; P < 0.01). Every 100 nmol/liter increase in SHBG was associated with a 31% reduced risk of preeclampsia [odds ratio (OR), 0.69; 95% confidence interval (CI), 0.55, 0.88; P < 0.01]. After adjusting for covariates in a multiple logistic regression model, the association between first trimester SHBG and preeclampsia remained significant (per 100 nmol/liter increase; OR, 0.66; 95% CI, 0.47, 0.92; P = 0.01). When subjects were stratified by body mass index (lean: body mass index, <25 kg/m²; overweight: body mass index, 25 kg/m²), overweight women had lower SHBG levels than lean women (286 ± 156 vs. 410 ± 166 nmol/liter; P < 0.01), and within each stratum, women with preeclampsia had lower SHBG levels than their respective controls. In a multivariable analysis, the association between SHBG and preeclampsia strengthened among lean women, such that every 100 nmol/liter increase in serum SHBG was associated with a 55% reduction in the risk of preeclampsia (OR, 0.45; 95% CI, 0.27, 0.77; P < 0.01), whereas in overweight women, the association was mitigated (OR, 1.02; 95% CI, 0.62, 1.69; P = 0.9). We conclude that increased early pregnancy insulin resistance is independently associated with subsequent preeclampsia. First trimester SHBG levels may be a useful biomarker for preeclampsia, especially among lean women who otherwise would be perceived to be at low risk.

This article has been cited by other articles:

				J. S. Gilbert, M. J. Ryan, B. B. LaMarca, M. Sedeek, S. R. Murphy, and J. P. Granger Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H541 - H550. [Abstract] [Full Text] [PDF]

				E. B. Magnussen, L. J. Vatten, T. I. Lund-Nilsen, K. A. Salvesen, G. D. Smith, and P. R. Romundstad Prepregnancy cardiovascular risk factors as predictors of pre-eclampsia: population based cohort study BMJ, November 10, 2007; 335(7627): 978 - 978. [Abstract] [Full Text] [PDF]

				R. Troisi, N. Potischman, and R. N. Hoover Exploring the Underlying Hormonal Mechanisms of Prenatal Risk Factors for Breast Cancer: A Review and Commentary Cancer Epidemiol. Biomarkers Prev., September 1, 2007; 16(9): 1700 - 1712. [Abstract] [Full Text] [PDF]

				J. M. Faupel-Badger, C.-C. Hsieh, R. Troisi, P. Lagiou, and N. Potischman Plasma Volume Expansion in Pregnancy: Implications for Biomarkers in Population Studies Cancer Epidemiol. Biomarkers Prev., September 1, 2007; 16(9): 1720 - 1723. [Abstract] [Full Text] [PDF]

				C. A. Hubel, G. Wallukat, M. Wolf, F. Herse, A. Rajakumar, J. M. Roberts, N. Markovic, R. Thadhani, F. C. Luft, and R. Dechend Agonistic Angiotensin II Type 1 Receptor Autoantibodies in Postpartum Women With a History of Preeclampsia Hypertension, March 1, 2007; 49(3): 612 - 617. [Abstract] [Full Text] [PDF]

				M. Tanaka, G. Jaamaa, M. Kaiser, E. Hills, A. Soim, M. Zhu, I. Y. Shcherbatykh, R. Samelson, E. Bell, M. Zdeb, et al. Racial Disparity in Hypertensive Disorders of Pregnancy in New York State: A 10-Year Longitudinal Population-Based Study Am J Public Health, January 1, 2007; 97(1): 163 - 170. [Abstract] [Full Text] [PDF]

				E. Parretti, A. Lapolla, M. Dalfra, G. Pacini, A. Mari, R. Cioni, C. Marzari, G. Scarselli, and G. Mello Preeclampsia in Lean Normotensive Normotolerant Pregnant Women Can Be Predicted by Simple Insulin Sensitivity Indexes Hypertension, March 1, 2006; 47(3): 449 - 453. [Abstract] [Full Text] [PDF]

				M. Wolf, C. A. Hubel, C. Lam, M. Sampson, J. L. Ecker, R. B. Ness, A. Rajakumar, A. Daftary, A. S. M. Shakir, E. W. Seely, et al. Preeclampsia and Future Cardiovascular Disease: Potential Role of Altered Angiogenesis and Insulin Resistance J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6239 - 6243. [Abstract] [Full Text] [PDF]

				M. Wolf, A. Shah, R. Jimenez-Kimble, J. Sauk, J. L. Ecker, and R. Thadhani Differential Risk of Hypertensive Disorders of Pregnancy among Hispanic Women J. Am. Soc. Nephrol., May 1, 2004; 15(5): 1330 - 1338. [Abstract] [Full Text] [PDF]

				R. Thadhani, J. L. Ecker, W. P. Mutter, M. Wolf, K. V. Smirnakis, V. P. Sukhatme, R. J. Levine, and S. A. Karumanchi Insulin Resistance and Alterations in Angiogenesis: Additive Insults That May Lead to Preeclampsia Hypertension, May 1, 2004; 43(5): 988 - 992. [Abstract] [Full Text] [PDF]

				K. Shinohara, A. Wakatsuki, K. Watanabe, N. Ikenoue, T. Fukaya, N. Sattar, J. Ramsey, N. Jamieson, and I. A. Greer Plasma Adiponectin Concentrations in Women With Preeclampsia * Response: Adiponectin Concentrations in Preeclampsia Hypertension, April 1, 2004; 43(4): e17 - e17. [Full Text] [PDF]

				R. Thadhani, W. P. Mutter, M. Wolf, R. J. Levine, R. N. Taylor, V. P. Sukhatme, J. Ecker, and S. A. Karumanchi First Trimester Placental Growth Factor and Soluble Fms-Like Tyrosine Kinase 1 and Risk for Preeclampsia J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 770 - 775. [Abstract] [Full Text] [PDF]

				J. E. Ramsay, N. Jamieson, I. A. Greer, and N. Sattar Paradoxical Elevation in Adiponectin Concentrations in Women With Preeclampsia Hypertension, November 1, 2003; 42(5): 891 - 894. [Abstract] [Full Text] [PDF]

				R. Tamimi, P. Lagiou, L. J. Vatten, L. Mucci, D. Trichopoulos, S. Hellerstein, A. Ekbom, H.-O. Adami, and C.-C. Hsieh Pregnancy Hormones, Pre-eclampsia, and Implications for Breast Cancer Risk in the Offspring Cancer Epidemiol. Biomarkers Prev., July 1, 2003; 12(7): 647 - 650. [Abstract] [Full Text] [PDF]

				E. W. Seely and C. G. Solomon Insulin Resistance and Its Potential Role in Pregnancy-Induced Hypertension J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2393 - 2398. [Abstract] [Full Text] [PDF]

				M. Wolf, L. Sandler, R. Jimenez-Kimble, A. Shah, J. L. Ecker, and R. Thadhani Insulin Resistance But Not Inflammation Is Associated With Gestational Hypertension Hypertension, December 1, 2002; 40(6): 886 - 891. [Abstract] [Full Text] [PDF]